Hostname: page-component-cb9f654ff-kl2l2 Total loading time: 0 Render date: 2025-07-31T14:04:26.482Z Has data issue: false hasContentIssue false
  • English
  • Français

Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine

Published online by Cambridge University Press:  16 April 2020

J. Rudolf ,
M. Ghaemi  and
S. Schmülling
J. Rudolf
Affiliation:
Klinik für Neurologie der Universität zu Köln, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany
M. Ghaemi
Affiliation:
Klinik für Neurologie der Universität zu Köln, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany
S. Schmülling
Affiliation:
Klinik für Neurologie der Universität zu Köln, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany
Get access

Summary

The atypical antipsychotic drug olanzapine has been proposed for treatment of dopaminergic psychosis in Parkinson's disease (PD). We report on a 68-year-old patient who developed a severe akinetic-rigid extrapyramidal syndrome, accompanied by additional paranoid symptoms, following olanzapine treatment of optic hallucinosis in PD. Olanzapine may also induce clinically relevant extrapyramidal side effects in PD patients.

Keywords

dopaminergic psychosisidiopathic Parkinson's diseaseolanzaphineorganic delusional disorder

Information

Type
Case report
Information
European Psychiatry , Volume 14 , Issue 6 , October 1999 , pp. 356 - 357
Copyright
Copyright © European Psychiatric Association 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Beasley, CTollefson, GTran, P. Safety of olanzapine J Clin Psychiatr 1997 ; 58 (Suppl 10) : 13–17.Google ScholarPubMed
Bymaster, FPCalligaro, DOFalcone, JFMarsh, RDMoore, NATye, NC, et al. Radioreceptor binding profile of the atypical antipsychotic agent olanzapine Neuropsychopharmacology 1996 ; 14 : 87–96.CrossRefGoogle Scholar
Chambers, RACaracansi, AWeiss, G. Olanzapine ovedose cause of acute extrapyramidal symptoms Am J Psychiatry 1998 ; 15 : 1630-1.Google Scholar
Friedman, J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease Neurology 1998 ; 50 : 1195-6.CrossRefGoogle ScholarPubMed
Friedman, JHLannon, MC. Clozapine-responsive tremor in Parkinson's disease Mov Disord 1990 ; 5 : 225-9.CrossRefGoogle ScholarPubMed
Graham, JMSussman, JDFord, KSSagar, HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note J Neurol Neurosurg Psychiatry 1998 ; 65 : 774-7.CrossRefGoogle ScholarPubMed
Moshkovitz, CMoses, HKlawans, HL. Levodopa-induced psychosis: A kindling phenomenon Am J Psychiatry 1978 ; 13 : 669-75.Google Scholar
Rich, SFriedman, JHOtt, BR. Risperidone versus clozapine for the treatment of drug-induced psychosis in Parkinson's patients J Clin Psychiatr 1995 ; 56 : 556-9.Google Scholar
Wolters, ECJansen, ENHTuynman-Qua, HGBergmans, PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease Neurology 1996 ; 47 : 1085-7.CrossRefGoogle ScholarPubMed
Tolosa, ESValldeoriola, FMarti, MJ. New and emerging strategies for improving levodopa treatment Neurology 1994 ; 44 (Suppl 6) : S35–S44.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.